The present invention provides a pharmaceutical composition in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a dose equivalent to a metered nominal dose of about 1.25 or about 2.5 micrograms of free base abediterol administered with the GenuairR inhaler. The present invention also provides said pharmaceutical composition for use in the treatment of respiratory disease such as asthma and chronic obstructive pulmonary disease COPD.